{"id":47006,"date":"2022-08-05T23:01:46","date_gmt":"2022-08-05T21:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/"},"modified":"2022-08-05T23:01:46","modified_gmt":"2022-08-05T21:01:46","slug":"axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/","title":{"rendered":"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock"},"content":{"rendered":"
\n

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) (\u201cAxonics\u201d), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the exercise in full by the underwriter of its option to purchase 262,500 additional shares. The gross proceeds from the offering to Axonics, before deducting estimated offering expenses, were approximately $128.5 million.\n<\/p>\n

<\/a><\/p>\n

\nBofA Securities acted as the sole book-running manager for the offering.\n<\/p>\n

\nThe shares described above were offered pursuant to a shelf registration statement on Form S-3, including a base prospectus, which was previously filed by Axonics with the Securities and Exchange Commission (\u201cSEC\u201d) on May 7, 2020 and became automatically effective upon filing. A final prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC and are available on the SEC\u2019s website located at http:\/\/www.sec.gov<\/a>. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained by contacting: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com<\/a>. The final terms of the offering were disclosed in the final prospectus supplement filed with the SEC.\n<\/p>\n

\nAbout Axonics, Inc.<\/b>\n<\/p>\n

\nBased in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAxonics:<\/b>
Neil Bhalodkar
\n
Investor Relations
\n
949-336-5293
\n
ir@axonics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) (\u201cAxonics\u201d), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47006","6":"format-standard","7":"category-industry"},"yoast_head":"\nAxonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) (\u201cAxonics\u201d), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T21:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220805005473\/en\/788134\/21\/Axonics_Logo_-_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock\",\"datePublished\":\"2022-08-05T21:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/\"},\"wordCount\":285,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005473\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/\",\"name\":\"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005473\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\",\"datePublished\":\"2022-08-05T21:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005473\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005473\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/","og_locale":"en_US","og_type":"article","og_title":"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock - Pharma Trend","og_description":"IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX) (\u201cAxonics\u201d), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 2,012,500 shares of its common stock at a price of $63.85 per share to the underwriter, which includes the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-05T21:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220805005473\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock","datePublished":"2022-08-05T21:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/"},"wordCount":285,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220805005473\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/","url":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/","name":"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220805005473\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","datePublished":"2022-08-05T21:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220805005473\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220805005473\/en\/788134\/21\/Axonics_Logo_-_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/axonics-announces-closing-of-public-stock-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-stock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Axonics\u00ae Announces Closing of Public Stock Offering and Full Exercise of Underwriter\u2019s Option to Purchase Additional Stock"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47006"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47006\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}